Functionalized Peptides As Antiviral Agents
Patent No. EP4051265 (titled "Functionalized Peptides As Antiviral Agents") was filed by Enanta Pharmaceuticals on Jul 19, 2021. The application was issued on Aug 20, 2025.
Patent Summary
The invention provides a compound of Formula (VI-6a), or its pharmaceutically acceptable salt, characterized by X being a cyano group (-CN) and A being an optionally substituted C1-C8 alkyl or optionally substituted heteroaryl. These compounds act as 3C-Like protease (3CLpro/Mpro) inhibitors, interfering with the processing of viral polyproteins to prevent coronavirus replication. They are intended for treating or preventing coronavirus infections (including alpha, beta, gamma, and delta coronaviruses, specifically SARS-CoV-1, SARS-CoV-2, and MERS-CoV) and associated respiratory disorders. The compounds may be administered as monotherapy or in combination with other antiviral, immunomodulatory, or anti-inflammatory agents via various pharmaceutical compositions, including oral, injectable depot, or rectal/vaginal formulations.
UPC Cases New
Latest UPC cases involving this patent.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP4051265
- Application Number
- EP21846991A
- Filing Date
- Jul 19, 2021
- Status
- Granted And Under Opposition
- Jul 18, 2025
- Publication Date
- Aug 20, 2025
- External Links
- Slate, Register , Google Patents